JP4516970B2 - Inhaler for basic drugs and method for producing the same - Google Patents
Inhaler for basic drugs and method for producing the same Download PDFInfo
- Publication number
- JP4516970B2 JP4516970B2 JP2006541822A JP2006541822A JP4516970B2 JP 4516970 B2 JP4516970 B2 JP 4516970B2 JP 2006541822 A JP2006541822 A JP 2006541822A JP 2006541822 A JP2006541822 A JP 2006541822A JP 4516970 B2 JP4516970 B2 JP 4516970B2
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- air
- inhalation
- acid
- air inlet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003570 air Substances 0.000 claims description 95
- 238000002360 preparation method Methods 0.000 claims description 76
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 52
- 239000002253 acid Substances 0.000 claims description 48
- 229960002715 nicotine Drugs 0.000 claims description 48
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 48
- 239000013543 active substance Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- 239000000443 aerosol Substances 0.000 claims description 12
- 150000007513 acids Chemical class 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 239000010410 layer Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- -1 polyethylene Polymers 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 7
- 239000011241 protective layer Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000012080 ambient air Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 235000011054 acetic acid Nutrition 0.000 claims description 5
- 210000000214 mouth Anatomy 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000011888 foil Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000000391 smoking effect Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 206010057852 Nicotine dependence Diseases 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 230000003434 inspiratory effect Effects 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 239000002585 base Substances 0.000 description 21
- 239000012876 carrier material Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000005586 smoking cessation Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920001824 Barex® Polymers 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 2
- 229960002525 mecamylamine Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940087730 nicorette Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 238000010944 pre-mature reactiony Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 125000002298 terpene group Chemical group 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
- A24F42/20—Devices without heating means
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
- A24F42/60—Constructional details
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
- A24F42/80—Manufacture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
本発明は塩基性活性物質、特にニコチンを、ヒトまたは動物の身体に吸入により投与するためのデバイスに関する。本発明はさらに、かかるデバイスを得るための製造方法、ならびに該デバイスの、禁煙、または必要な状況におけるニコチン渇望の喫煙によらない充足のための使用に関する。 The present invention relates to a device for administering a basic active substance, in particular nicotine, to the human or animal body by inhalation. The invention further relates to a manufacturing method for obtaining such a device, as well as the use of the device for smoking cessation or for the fulfillment of nicotine craving without smoking in a necessary situation.
吸気中に吸入される空気を介してニコチンを投与するためのニコチン吸入器はここ数年の間に知られるようになった(例えば、米国特許第4 917 120号および米国特許第5 167 242号)。また、ここ何年かの間に、ニコチン吸入器は、禁煙製品として欧州の複数の国で市販されるようになった(「Nicorette(登録商標)」、Pharmacia/Pfizer)。後者のニコチン吸入器は、しかしながら、このデバイスでは吸入時にわずかな量のニコチンしか効力を発揮しないため、広くは用いられていない。これは、特に、既知の吸入器技術の根本的な欠陥と、これらの技術により達成できる耐容性によるものである。特に、ニコチンのアルカリ性により惹起される気道粘膜への局所的な刺激作用は、これが咳の衝動を催し、その結果、吸入器により放出されたニコチン蒸気の吸収が減少するため不利である。このように、極めて少量のニコチンしか身体に吸収されない。 Nicotine inhalers for administering nicotine via air inhaled during inspiration have become known over the last few years (eg, US Pat. No. 4,917,120 and US Pat. No. 5,167,242). ). Also, over the last few years, nicotine inhalers have been marketed as non-smoking products in several European countries (“Nicorette®”, Pharmacia / Pfizer). The latter nicotine inhaler, however, is not widely used because only a small amount of nicotine is effective when inhaled with this device. This is due in particular to the fundamental deficiencies of known inhaler technologies and tolerability that can be achieved with these technologies. In particular, the local irritation to the airway mucosa caused by the alkaline nature of nicotine is disadvantageous because it causes a cough impulse and consequently reduces the absorption of nicotine vapor released by the inhaler. Thus, only a very small amount of nicotine is absorbed by the body.
したがって、本発明の目的は、可能な限り低刺激かつ強力に、気道を介したニコチンの吸収を可能にするニコチン吸入器を提供することであった。 Accordingly, it was an object of the present invention to provide a nicotine inhaler that allows absorption of nicotine through the airways with as little irritation and strength as possible.
この目的は、主請求項およびこれに従属する請求項に記載されたデバイス、ならびに、請求項19およびこれに従属する請求項に記載された製造方法により達成される。 This object is achieved by the device described in the main claim and the subordinate claims and the manufacturing method described in claim 19 and the subordinate claims.
したがって、本発明によるデバイスは、ニコチン塩基または/および他の揮発性で吸入可能な塩基性活性物質を含有する第1の調製物を含み、かつ、第2の調製物または複数のさらなる調製物であって、前記第2の調製物または少なくとも1つの前記さらなる調製物が、揮発性で吸入に適した少なくとも1種の酸を含有するものをさらに含むことを特徴とする。したがって、本発明によるデバイスは、吸入時に、活性塩基物質(例えば、ニコチン塩基)だけでなく、1種また2種以上の揮発性酸化合物も同時に吸入されることを特徴とする。 Accordingly, the device according to the invention comprises a first preparation containing nicotine base or / and other volatile inhalable basic active substances, and in a second preparation or a plurality of further preparations. Wherein the second preparation or at least one of the further preparations further comprises one containing at least one acid that is volatile and suitable for inhalation. Therefore, the device according to the present invention is characterized in that not only the active base substance (for example, nicotine base) but also one or more volatile acid compounds are simultaneously inhaled during inhalation.
本発明によるデバイスは、塩基性の剤、特にニコチンの、ヒトまたは動物の身体への吸入による投与に適している。好適な塩基性の剤は、例えば、セレジリンおよび/またはメカミラミンである。ニコチンとメカミラミンとの組み合わせは、禁煙のために特に好ましく用いられる。 The device according to the invention is suitable for the administration of basic agents, in particular nicotine, by inhalation into the human or animal body. Suitable basic agents are, for example, selegiline and / or mecamylamine. The combination of nicotine and mecamylamine is particularly preferably used for smoking cessation.
ニコチン塩基(または他の活性剤塩基)を含む第1の調製物と、揮発酸を含むさらなる調製物とが同時に存在することにより、ニコチン塩基と揮発酸とが吸入の最中に揮発し、塩基性および酸性の蒸気の混合が、デバイス内で対応するニコチン塩(または、他の活性剤塩基の対応する塩)の形成をもたらす。この塩は、液滴の形態または粒子形態で、吸入された空気と共に気道に入る。粘膜の塩に対する中性反応のために、このタイプの吸入は既知の吸入デバイスによって達成できるものよりも顕著に良好な耐容性を示す。 The simultaneous presence of the first preparation containing nicotine base (or other active agent base) and the further preparation containing volatile acid causes nicotine base and volatile acid to volatilize during inhalation and Mixing of acidic and acidic vapors results in the formation of the corresponding nicotine salt (or the corresponding salt of other active agent bases) within the device. This salt enters the respiratory tract with inhaled air in the form of droplets or particles. Due to the neutral response to mucosal salt, this type of inhalation is significantly better tolerated than can be achieved with known inhalation devices.
これに関して、前記第1の、ニコチン塩基含有調製物と、前記第2の、酸含有調製物とが、デバイス内の別々の場所に適用されることが好ましい。こうすることにより、吸入時に、一部の気流が第1の調製物上を流れ、他の気流が第2の調製物上を流れ、次いで2つの気流(その中に揮発したニコチン塩基と酸とを含む)が混合し、その後吸入され得るように、空気流入チャネルを構成することができる。 In this regard, it is preferred that the first, nicotine base-containing preparation and the second, acid-containing preparation are applied at different locations within the device. By doing so, upon inhalation, some airflows flow over the first preparation, other airflows flow over the second preparation, and then two airflows (the nicotine base and acid volatilized therein). Air inlet channels can be configured so that they can be mixed and then inhaled.
吸入の最中、第1の調製物に含まれる活性剤塩基(例えばニコチン塩基)と、第2の調製物に含まれる揮発酸は受動的に揮発する。この過程は、熱の適用により任意に加速することができる。このための好適な手段は当業者に知られている。 During inhalation, the active agent base (eg, nicotine base) contained in the first preparation and the volatile acid contained in the second preparation are volatilized passively. This process can be arbitrarily accelerated by the application of heat. Suitable means for this are known to those skilled in the art.
本発明によるデバイスが用いられる際には、そこを流れる周囲空気によりエアロゾルが形成される。蒸気中に高濃度の活性剤塩基と高濃度の酸とが存在する場合には特にそうである。このエアロゾルの形成はニコチン塩の低い揮発性によるものであり、塩混合物または塩溶液滴が形成される。エアロゾルの形成は同時に、ニコチンがもはや遊離形態で存在せず、外部気相を介してアルカリとして作用することがもはやできなくなるため、耐容性の実質的な増大の理由となる。この結果、肺胞へのエアロゾル粒子の粒子沈着のみが、肺における活性剤の適用と吸収(absorption)(再吸収(resorption))とをもたらすことができる。水に部分的に溶解した塩成分としての、または固体分散体としてのこれらのエアロゾル滴は、(アルカリ性ではなく)中性の粘膜反応により、従来技術で知られているデバイスによって可能なものよりもはるかに良好な耐容性を示す。
エアロゾルの形成は有用だが、本発明による治療結果を達成するのに必須ではない。全体として、供給される蒸気の高度の希釈(そうしてエアロゾルの形成を抑制する)は、耐容性に関して一層有用であり得る。
When the device according to the invention is used, an aerosol is formed by the ambient air flowing therethrough. This is especially true when high concentrations of activator base and high concentrations of acid are present in the vapor. The formation of this aerosol is due to the low volatility of the nicotine salt, forming a salt mixture or salt solution droplet. The formation of the aerosol is at the same time a reason for the substantial increase in tolerability, since nicotine is no longer present in free form and can no longer act as alkali via the external gas phase. As a result, only the deposition of aerosol particles in the alveoli can result in the application and absorption (resorption) of the active agent in the lung. These aerosol droplets, either as a salt component partially dissolved in water or as a solid dispersion, are more than possible by devices known in the prior art due to neutral mucosal reactions (rather than alkaline) It is much better tolerated.
Although aerosol formation is useful, it is not essential to achieve a therapeutic result according to the present invention. Overall, a high dilution of the supplied vapor (thus suppressing the formation of aerosols) may be more useful with regard to tolerability.
本発明の吸入システムにより形成されるエアロゾル粒子のサイズは、とりわけ、気流の速度(流速)と混合領域における個々の気体成分(それぞれ、塩基性活性剤および酸)の濃度とに依存する。肺胞での吸収に有利なのは、サイズが10μm未満(平均径)、特に5〜10μmのエアロゾル粒子である。 The size of the aerosol particles formed by the inhalation system of the present invention depends inter alia on the velocity of the air stream (flow rate) and the concentration of the individual gaseous components (basic active agent and acid, respectively) in the mixing zone. Advantageous for absorption in the alveoli are aerosol particles with a size of less than 10 μm (average diameter), in particular 5-10 μm.
好ましい態様では、吸入デバイスは、第1の空気流入口、第2の空気流入口および空気流出口を含む。これらの開口は、第1の空気流入口を通って流れる気流が主に前記第1の調製物上を通り、第2の空気流入口を通って流れる気流が主に前記第2のまたはさらなる調製物上を通り、この2つの気流がその経路において後に混合し、前記流出口を通ってデバイスを出て行くように配置される。 In a preferred embodiment, the inhalation device includes a first air inlet, a second air inlet and an air outlet. These openings are such that the airflow flowing through the first air inlet is primarily over the first preparation and the airflow flowing through the second air inlet is primarily the second or further preparation. Passing over the object, the two air streams are arranged to mix later in the path and exit the device through the outlet.
デバイスが、内部に縦長の凹部、溝またはチャネルを有し、これにより第1および第2の空気流入チャネル、および空気逃しチャネルが形成されることがさらに好ましい。これらの通気経路は、それぞれ、前記空気流入口および空気流出口を介して外部に向かって開いている。前記第1の調製物は、第1の空気流入チャネルを形成する縦長の凹部に位置し、前記第2の調製物は、第2の空気流入チャネルを形成する縦長の凹部に位置する。各調製物が、それぞれの空気流入口の近くに適用されることが好ましい。 More preferably, the device has longitudinal recesses, grooves or channels therein, thereby forming first and second air inflow channels and air escape channels. These ventilation paths are opened outward through the air inlet and the air outlet, respectively. The first preparation is located in an elongated recess that forms a first air inlet channel, and the second preparation is located in an elongated recess that forms a second air inlet channel. Each preparation is preferably applied near the respective air inlet.
一般的に、2つの成分(活性剤塩基、酸)のモル蒸発速度がおよそ等モル比であることが意図される。記載のとおり、ニコチン含有調製物と酸含有調製物とが、付随する給気口を有する2つの別個の給気チャネルに適用されている場合は、それぞれの放出速度は、特に、2つのチャネルにおけるフロー条件により制御することができる。例えば、100μg/10秒の放出速度を第1の開口、したがって第1の給気チャネルを通って流れる気流にもたらすことができる。この場合、酸性分として酢酸が用いられていれば、約50mg/10秒の放出速度が前記第2の気流にとって好適である。 In general, it is contemplated that the molar evaporation rates of the two components (activator base, acid) are approximately equimolar ratios. As described, when the nicotine-containing preparation and the acid-containing preparation are applied to two separate air supply channels with associated air inlets, the respective release rates are in particular in the two channels. It can be controlled by flow conditions. For example, a release rate of 100 μg / 10 seconds can be provided for the airflow flowing through the first opening and hence the first air supply channel. In this case, if acetic acid is used as the acidic component, a release rate of about 50 mg / 10 seconds is suitable for the second air stream.
得ることが可能な放出速度に関しては、1〜10秒継続し、かつ、その間0.1〜1l/分の吸気速度に達する1回の吸気過程の最中に、本発明の吸入デバイスは、5〜250μg、好ましくは10〜100μgのニコチン塩基または別の塩基性の剤を、前記調製物から吸気中に放出する。例えば、10秒継続し、かつ、吸気速度が0.1〜1l/分である1回の呼吸の最中に、100μgのニコチン塩基を投与することが可能である。この放出速度は、治療目的に適する。 With regard to the release rate that can be obtained, the inhalation device of the present invention has a duration of 1 to 10 seconds, during which one inhalation process reaches 0.1 to 1 l / min. ~ 250 μg, preferably 10-100 μg of nicotine base or another basic agent is released from the preparation during inhalation. For example, 100 μg of nicotine base can be administered during a single breath that lasts 10 seconds and has an inspiration rate of 0.1-1 l / min. This release rate is suitable for therapeutic purposes.
吸気の過程を可能な限り妨げないように、デバイスはその構造の全体において広い通路断面積を有することが好ましい。これは特に、空気流入口の管断面(conduit cross-section)と空気流出口の管断面が、吸気過程中の口腔における負差圧(negative differential pressure)が300Paを超えないように設定されている場合に当てはまる。 The device preferably has a wide passage cross-sectional area throughout its structure so as not to disturb the inhalation process as much as possible. In particular, the conduit cross-section of the air inlet and the tube cross-section of the air outlet are set so that the negative differential pressure in the oral cavity during the inhalation process does not exceed 300 Pa. The case is true.
揮発酸としては、酢酸が好ましく用いられる。他の酸も、室温(約15〜25℃)で揮発性であるか、または熱衝撃(約100℃まで)により蒸気相に転換できれば、同様に用いてもよい(例えば、乳酸、リンゴ酸、プロピオン酸)。異なる酸の組み合わせでさえも用いることができる。酢酸は、その高い揮発性により、より低濃度かつより多くの総量で、なおかつ添加剤と組み合わせて用いる。揮発性で吸入可能な塩基性活性剤は、特に、揮発性であるか、または上記の温度で蒸気相に転化され得る剤と理解される。 Acetic acid is preferably used as the volatile acid. Other acids may be used as well (for example, lactic acid, malic acid, if they are volatile at room temperature (about 15-25 ° C.) or can be converted to the vapor phase by thermal shock (up to about 100 ° C.). Propionic acid). Even combinations of different acids can be used. Acetic acid is used in lower concentrations and higher total amounts due to its higher volatility and in combination with additives. Volatile and inhalable basic active agents are understood in particular as agents which are volatile or can be converted into the vapor phase at the temperatures mentioned above.
さらにまた、具体的な態様によれば、活性剤含有調製物は、吸入に適した少なくとも1種の溶媒(好ましくはエタノール)および/または少なくとも1種の揮発性補助物質(好ましくはメントール)をさらに含む。酸含有調製物は、同様に、少なくとも1種のかかる溶媒および/または少なくとも1種の揮発性助剤を含む。好適な揮発性助剤は、特に、快く感じられる香味物質および芳香物質である(例えば、リモネン、ユーカリプトール、ミント油、カンファー、またはテルペン群からの他の物質。前記物質の組み合わせを含む)。 Furthermore, according to a specific embodiment, the active agent-containing preparation further comprises at least one solvent suitable for inhalation (preferably ethanol) and / or at least one volatile auxiliary substance (preferably menthol). Including. The acid-containing preparation likewise comprises at least one such solvent and / or at least one volatile aid. Suitable volatile auxiliaries are, in particular, pleasantly flavored and aromatic substances (for example limonene, eucalyptol, mint oil, camphor, or other substances from the terpene group, including combinations of said substances) .
本発明はさらに上記デバイスの製造方法を包含する。これらの方法は、一般的に以下の工程を含む。
−深絞りまたは当業者に知られた他の成形方法(例えば射出成形)により、前記第1の調製物を受ける縦長の窪んだ第1の凹部と、前記第2の調製物を受ける縦長の窪んだ第2の凹部とを含む成形部分を作製する工程、
−ニコチン塩基または他の塩基性活性剤を含む所定量の第1の調製物を、前記第1の凹部に導入する工程、
−1種または2種以上の酸を含む所定量の第2の調製物を、前記第2の凹部に導入する工程。
The present invention further includes a method for manufacturing the above device. These methods generally include the following steps.
A vertically elongated first recess for receiving the first preparation and a longitudinal recess for receiving the second preparation by deep drawing or other molding methods known to those skilled in the art (eg injection molding). Producing a molded part including the second recess,
Introducing a predetermined amount of a first preparation comprising nicotine base or other basic active agent into said first recess;
A step of introducing a predetermined amount of the second preparation containing one or more acids into the second recess.
本発明によるデバイスは、深絞りにより作製した成形部分を利用することにより簡単かつ低コストで作製することができる。この目的のために適した好ましい材料は、塩基性の剤、特にニコチンに対して不透過性の被覆を有するポリエステル材料である。この目的のために好適なのは、とりわけ、アクリロニトリルとメタクリレートとのコポリマー(Barex(登録商標)、BP)である。ポリエチレンテレフタレートとBarexとの積層シートが好ましく用いられる。 The device according to the present invention can be manufactured easily and at low cost by using a molded part manufactured by deep drawing. A preferred material suitable for this purpose is a polyester material with a basic agent, in particular a coating impermeable to nicotine. Suitable for this purpose are inter alia copolymers of acrylonitrile and methacrylate (Barex®, BP). A laminated sheet of polyethylene terephthalate and Barex is preferably used.
深絞りにより、縦長の凹部が成形部分に設けられ、これが2つの給気路を形成する。さらに、前記2つの凹部に接続してさらなる縦長の凹部を設けてもよく、これは空気流出チャネルを形成する。空気流入チャネルおよび空気流出チャネルは、本質的に管状の形状であるが、これらはまた、それとは異なる形状であってもよい。 Due to the deep drawing, a vertically long recess is provided in the molded part, which forms two air supply channels. Furthermore, a further longitudinal recess may be provided in connection with the two recesses, which forms an air outflow channel. The air inflow channel and air outflow channel are essentially tubular in shape, but they may also be of different shapes.
凹部が設けられた成形部分は、デバイスの底部を形成する。上部は、対応して設けられた凹部を有する第2の成形部分により、または、カバーの役割をする平坦なフィルムもしくは層により形成されていてもよい。上部と底部は、調製物の適用後、既知の方法(たとえば、接着結合、シーリング)で互いに連結される。 The molded part provided with the recess forms the bottom of the device. The upper part may be formed by a second molded part having a correspondingly provided recess or by a flat film or layer serving as a cover. The top and bottom are connected to each other in a known manner (eg adhesive bonding, sealing) after application of the preparation.
1つまたは2つ以上の成形部分に給気チャネルを形成する凹部は、追加の膨部(深絞りにより同様に生成されてもよい)を設けることにより、それぞれの揮発成分の蒸発速度が幾何学的に制限され得るような形状にしてもよい。この方策は、活性剤塩基と酸との等モル量での好ましい送達を達成するさらなる可能性をもたらす。
本デバイスは、少なくとも部分的に、しかしながら、好ましくは全体が、活性剤に対して不透過性な材料、特に上記の被覆を備えたポリエステル材料、および/または金属ホイル、またはこれらの材料の組み合わせから成っている。
The recesses that form the air supply channels in one or more molded parts may be provided with additional bulges (which may also be generated by deep drawing), so that the evaporation rate of each volatile component is geometric. The shape may be limited. This strategy offers the additional possibility of achieving favorable delivery of equimolar amounts of active agent base and acid.
The device is at least partly, however, preferably entirely from a material that is impermeable to the active agent, in particular a polyester material with the coating described above, and / or a metal foil, or a combination of these materials It is made up.
前記調製物を製造するための基材として好適なのは、原則的に、ニコチン塩基もしくは他の活性剤の塩基または既述の揮発酸を受け、かつ、吸入条件下でこれらの物質を周辺空気への蒸発により放出する貯蔵部を作製するために用いることができる任意の材料である。この目的のために好適な材料は当業者に知られている。 Suitable as substrates for the preparation of the preparations in principle receive nicotine base or other active agent bases or the stated volatile acids and, under inhalation conditions, these substances to ambient air. Any material that can be used to make a reservoir that releases by evaporation. Suitable materials for this purpose are known to those skilled in the art.
好適な材料は、例えば、経皮治療システムの活性物質貯蔵部の製造に用いられるような高分子材料である。この工程において、活性物質(または酸)は、高分子基材(例えば、ポリアクリレート)に、任意に補助物質の添加とともに、溶解もしくは分散され、そして、得られた塊を不活性な支持体上にコーティングして乾燥させる。既知の含量の活性剤または酸を有する、所定の表面積および層厚の部分を、乾燥した活性剤含有層から分離する。記載したとおり、これらの部分を、次に、本発明のデバイス内に、上述の調製物として挿入することができる。本デバイスの通気空間内に導入されるシート状調製物の好適な層厚および表面積は、薬学的プラクティスに由来する。 Suitable materials are, for example, polymeric materials such as those used in the manufacture of active substance reservoirs for transdermal therapeutic systems. In this step, the active substance (or acid) is dissolved or dispersed in a polymeric substrate (eg polyacrylate), optionally with the addition of auxiliary substances, and the resulting mass is placed on an inert support. Coat and dry. A portion of a given surface area and layer thickness with a known content of active agent or acid is separated from the dried active agent-containing layer. As described, these parts can then be inserted as a preparation as described above into the device of the invention. The preferred layer thickness and surface area of the sheet-like preparation introduced into the vent space of the device is derived from pharmaceutical practice.
本発明によるデバイス内に挿入されるニコチン調製物は、典型的に10重量%の含量を有し、用量は典型的には500mgである。それぞれの個々のケースにおいて用いられる濃度および用量は、これらの例示的な値から逸脱してもよい。特に、活性物質の含量は1〜80重量%、そして用量は10〜1000mgであってもよい。
高分子基材として好適なのは、特に、ポリエチレン、ポリプロピレン、シリコーンポリマー(ポリジメチルシロキサン)およびポリ(メト)アクリレートを含む群からのポリマーである。
The nicotine preparation inserted in the device according to the invention typically has a content of 10% by weight and the dose is typically 500 mg. The concentrations and doses used in each individual case may deviate from these exemplary values. In particular, the content of active substance may be 1 to 80% by weight and the dose may be 10 to 1000 mg.
Suitable as polymeric substrates are in particular polymers from the group comprising polyethylene, polypropylene, silicone polymers (polydimethylsiloxane) and poly (meth) acrylates.
上記調製物はさらに、熱可塑性ポリマーを用いて製造することができ、同ポリマーは液化され、そして成分(塩基性活性剤および/または酸)は、熱いポリマーに量り入れる。依然として液状の調製物を、深絞りされた本吸入デバイスのこの目的のために意図された位置に適用し、放置して固化させる。 The above preparation can further be made with a thermoplastic polymer, which is liquefied and the components (basic active agent and / or acid) are weighed into the hot polymer. The still liquid preparation is applied in the position intended for this purpose of the deeply drawn inhalation device and left to solidify.
本発明のさらなる変形によれば、シリコーンポリマー(ポリジメチルシロキサン)と架橋剤(例えば、プラチナ含有架橋剤)との混合物が基材として用いられる。ニコチン塩基または揮発酸成分は、液状形態で、この混合物に冷条件下で量り入れる。この混合物の所定量を、この目的のために意図されたそれぞれの位置に適用する。デバイスを閉じた後、これに熱を適用して後処理し、これにより、活性剤放出調製物の3次元構造が形成される。 According to a further variant of the invention, a mixture of a silicone polymer (polydimethylsiloxane) and a crosslinker (eg a platinum-containing crosslinker) is used as the substrate. The nicotine base or volatile acid component is weighed into the mixture in a liquid form under cold conditions. A predetermined amount of this mixture is applied to each position intended for this purpose. After the device is closed, it is post-treated by applying heat, thereby forming a three-dimensional structure of the active agent release preparation.
活性剤含有または酸含有調製物は、好ましくは、各給気チャネルの空気流入口の近くに適用される。
本デバイスを閉じるのに利用される材料は、好ましくは、上記の通り、揮発性成分に対して不透過性の材料である。
The activator-containing or acid-containing preparation is preferably applied near the air inlet of each air supply channel.
The material utilized to close the device is preferably a material that is impermeable to volatile components, as described above.
さらなる好ましい態様において、吸入デバイスは、その製造後、塩基性の剤に対して不透過性の、剥離可能な保護層で被覆される。この保護層は、使用の直前に、使用者自身によって除去される。適用された保護層により、塩基性活性物質を含有する区画と、酸を含有する区画とが形成され、両区画は、互いに、実質的に気密的な様式で隔離され、かつ、周辺空気から密閉される。このようにすると、成分の時期尚早な反応とエージングとが防止される。保護層を除去した後でのみ、両区画間でガス交換が再び生じ得る。
必要に応じて、空気流入口および空気流出口もまた、保護フィルムで被覆される。
In a further preferred embodiment, the inhalation device is coated after its manufacture with a peelable protective layer that is impermeable to basic agents. This protective layer is removed by the user himself immediately before use. The applied protective layer forms a compartment containing a basic active substance and a compartment containing an acid, both compartments being isolated from each other in a substantially airtight manner and sealed from ambient air. Is done. In this way, premature reaction and aging of the components are prevented. Only after removing the protective layer can the gas exchange occur again between the two compartments.
If necessary, the air inlet and the air outlet are also covered with a protective film.
本デバイスは、禁煙のため、または必要な状況におけるニコチン渇望の喫煙によらない充足のために有利に用いることができる。
本発明を、例を用いて、そして、添付の図面を用いた図式的な表示により解説する。参照番号の意味は、別記のない限り、全ての図面において同一である。
The device can be advantageously used for smoking cessation or for non-smoking sufficiency of nicotine cravings in necessary situations.
The invention will now be described by way of example and by means of a schematic representation using the accompanying drawings. The meanings of the reference numbers are the same in all drawings unless otherwise specified.
図1Aは、商業的形態の本発明によるデバイス(1)を示す(断面表示)。デバイスは外壁(2)により形成されている。それは2つの通気チャネル(a、b)を有し、そのおよそ中央で拡張して、チャンバー(3a、3b)の1つをそれぞれ形成し、その後合流して空気逃しチャネル(7)を形成する。チャンバー(3a、3b)内には、ニコチン含有調製物(5)および酸含有調製物(4)がそれぞれ存在する。
図1Aは、使用前の本発明の条件を示してる。通気チャネル(a、b)の流入口および流出口は依然閉じられており、チャンバー(3a、3b)は、2つの成分(4、5)の混合が未だ生じ得ないように、互いに膜(13)により分離されている。
FIG. 1A shows a device (1) according to the invention in commercial form (cross-sectional view). The device is formed by the outer wall (2). It has two vent channels (a, b) and expands approximately in the middle to form one of the chambers (3a, 3b), respectively, and then merge to form an air escape channel (7). In the chambers (3a, 3b) there are nicotine-containing preparation (5) and acid-containing preparation (4), respectively.
FIG. 1A shows the conditions of the present invention prior to use. The inlets and outlets of the ventilation channels (a, b) are still closed, and the chambers (3a, 3b) are mutually connected to the membranes (13 so that mixing of the two components (4, 5) cannot yet occur. ).
図1Bは、膜(13)を開放し(例えば、熱の作用によりまたは押し込むことにより)、流入口および流出口(A、B、C)を開放した後の作動条件下における、図1Aに示したデバイスを示す(同様に、長手方向断面)。流入口および流出口は、例えば、デバイスに設けられたミシン目(図1Aの11、12)に沿って破り開けるかまたは裂き開くことにより開放してもよい(層(8)は、図1Bには示さず)。 FIG. 1B shows in FIG. 1A under operating conditions after opening the membrane (13) (eg, by the action of heat or by pushing in) and opening the inlet and outlet (A, B, C). Device (similarly in longitudinal section). The inlet and outlet may be opened (for example, layer (8) in FIG. 1B) by tearing or tearing along perforations (11, 12 in FIG. 1A) provided in the device. Is not shown).
吸気の際、空気は、一方で、空気流入口(A)および給気チャネル(a)を通って、他方で、空気流入口(B)および給気チャネル(b)を通って流れる。破線矢印は、吸入中の空気の流向を示している。2つの給気チャネル(a、b)は合わさり、空気流出口(C)を有する空気逃しチャネル(7)を形成する。給気チャネル(a)の領域には、流入口(A)の直後にニコチン含有調製物(5)があり、給気チャネル(b)の領域には、流入口(B)の直後に酸含有調製物(4)がある。空気がそこを通って流れると、ニコチンが調製物(5)から空気チャネル(a)中に揮発し、酸性化合物が調製物(4)から空気チャネル(b)中に蒸発する。空気逃しチャネル(7)の領域では、アルカリ性の蒸気と酸性の蒸気とが混合され、そしておよそ中性から若干酸性の条件が達成される。周辺空気とそこに含まれるニコチン塩とからなる形成されたエアロゾルは、流出口(C)を通って、好ましくは口腔を介して吸入される。 During inspiration, air flows on the one hand through the air inlet (A) and the air supply channel (a) and on the other hand through the air inlet (B) and the air supply channel (b). Dashed arrows indicate the direction of air flow during inhalation. The two air supply channels (a, b) are combined to form an air escape channel (7) with an air outlet (C). In the region of the air supply channel (a) there is a nicotine-containing preparation (5) immediately after the inlet (A), and in the region of the air supply channel (b) there is an acid containing immediately after the inlet (B). There is a preparation (4). As air flows through it, nicotine volatilizes from the preparation (5) into the air channel (a) and acidic compounds evaporate from the preparation (4) into the air channel (b). In the region of the air escape channel (7), alkaline and acidic vapors are mixed and approximately neutral to slightly acidic conditions are achieved. Aerosol formed of ambient air and nicotine salt contained therein is inhaled through the outlet (C), preferably via the oral cavity.
図1Cは、図1Bに図式的に示した吸入デバイスの面Xにおける断面を示す。空気流入チャネル(a、b)は、これらが窪んだ形状を有するように深絞りにより事前に形成する。空気チャネル(a、b)の領域には、活性剤含有調製物(5)と、酸含有調製物(4)とがそれぞれ存在する。デバイスは、下側を平坦な、ニコチン不透過性の層(8)で被覆される。 FIG. 1C shows a cross-section at plane X of the inhalation device schematically shown in FIG. 1B. The air inflow channels (a, b) are pre-formed by deep drawing so that they have a recessed shape. In the region of the air channel (a, b) there is an active agent-containing preparation (5) and an acid-containing preparation (4), respectively. The device is covered with a flat, nicotine-impermeable layer (8) on the underside.
図2Aは、商業的形態の、本発明による吸入デバイスのさらなる態様を(長手方向の断面で)示す。流入口および流出口(A、B、C)は依然閉ざされている。チャネル(a、b)の中央領域は拡張され、それぞれのチャンバー(3a、3b)を形成する。個々の調製物(4、5)のチャンバー(3a、3b)は、調製物の混合が未だ可能とならないように、隣り合って、かつ、互いに空間的に分離して配置される(使用前の状態)。 FIG. 2A shows a further embodiment (in longitudinal section) of the inhalation device according to the invention in commercial form. The inlet and outlet (A, B, C) are still closed. The central region of the channel (a, b) is expanded to form the respective chamber (3a, 3b). The chambers (3a, 3b) of the individual preparations (4, 5) are arranged next to each other and spatially separated from each other (before use) so that mixing of the preparations is not yet possible. Status).
図2Bは、図2Aに図式的に示した吸入デバイスの面Xにおける断面を示す。空気流入チャネル(a、b)およびチャンバー(3a、3b)は、外壁(2)における深絞りにより事前形成され、窪んだ形状である。チャンバー(3a、3b)の内部には、活性物質含有調製物(5)および酸含有調製物(4)がそれぞれ存在する。デバイスは、下側を平坦な、ニコチン不透過性の層(8)で被覆される。 FIG. 2B shows a cross section in plane X of the inhalation device schematically shown in FIG. 2A. The air inflow channels (a, b) and the chambers (3a, 3b) are pre-formed by a deep drawing in the outer wall (2) and have a recessed shape. Inside the chambers (3a, 3b) there are active substance-containing preparation (5) and acid-containing preparation (4), respectively. The device is covered with a flat, nicotine-impermeable layer (8) on the underside.
図2Cは、図2Aおよび図2Bに示した態様の長手方向のさらなる断面である。デバイスは、すぐに使用可能な状態で示されている。図2Aに記載したデバイスを使用するには、使用前に、これを、例えばミシン目もしくは弱くしたライン(weakened line)の形態で提供され得るライン(14)に沿って折りたたみ、中央に沿って折りたたむことにより、2つの通気チャネル(a、b)およびチャンバー(3a、3b)が、長手方向において、互いの上に位置するようにする。空気流入および空気流出チャネルの開口は、それぞれ、例えば、この目的のために設けられたミシン目(11、12)に沿って破り開けることにより開放してもよい。このようにして、機能的な吸入デバイスが得られる。破線矢印は、吸入中の気流の方向を示している。チューブまたはマウスピース(9)を2つの流出口(C、C’)上に滑り込ませることができ、これにより合体した空気流出チャネル(7’)および合体した流出口(D)が形成される。 FIG. 2C is a further longitudinal cross section of the embodiment shown in FIGS. 2A and 2B. The device is shown ready for use. To use the device described in FIG. 2A, before use, it is folded along a line (14), which can be provided in the form of perforations or weakened lines, and folded along the center. This ensures that the two vent channels (a, b) and the chambers (3a, 3b) lie on top of each other in the longitudinal direction. The openings of the air inflow and air outflow channels may each be opened, for example, by tearing along perforations (11, 12) provided for this purpose. In this way a functional inhalation device is obtained. Dashed arrows indicate the direction of airflow during inhalation. The tube or mouthpiece (9) can be slid over the two outlets (C, C '), thereby forming a combined air outlet channel (7') and a combined outlet (D).
図2Dは、図2Cに示した作動可能なデバイスの面Xにおける断面を示す。深絞りされた壁(2、2’)と層(8、8’)とで形成されたチャンバー(3a、3b)は、互いの上に位置する。
図2Eは、図2Cに示した作動可能なデバイスの面Yにおける断面を示す。破線矢印は、吸入時の気流の方向を示す。吸気の間、気流(A、B)は、別々のチャネル(a、b)を通って流れ、チャンバー(3a、3b)内に位置する調製物(4、5)上を通過する。生じた蒸気またはエアロゾルは、チューブまたはマウスピース(9)で形成された空気流出チャネル(7’)の領域で合わさり、流出口(D)を介してデバイスから出て行く。
FIG. 2D shows a cross section in plane X of the operable device shown in FIG. 2C. Chambers (3a, 3b) formed by deep-drawn walls (2, 2 ′) and layers (8, 8 ′) are located on top of each other.
FIG. 2E shows a cross section in plane Y of the operable device shown in FIG. 2C. Dashed arrows indicate the direction of airflow during inhalation. During inspiration, the air stream (A, B) flows through separate channels (a, b) and passes over the preparation (4, 5) located in the chamber (3a, 3b). The resulting vapor or aerosol meets in the region of the air outflow channel (7 ′) formed by the tube or mouthpiece (9) and exits the device via the outlet (D).
図3Aおよび3Bは、本発明によるデバイスのさらなる態様を(透視図法で)示しており、図3Bには、その中に円筒状インサート(31)を挿入することができるチューブまたはマウスピース(30)が記載されている。インサート(31)の内部空間は、長手方向に伸びる分割壁(32)により、2つのチャンバー(33、34)に分かれており、該チャンバーは、それぞれ活性剤調製物と酸成分とを受け入れる役割を果たす(図示せず)。インサートは、円筒状容器(35)で取り囲まれている(図3Aでは、これは部分的に切り欠いて記載してある)。後端の領域では、開口(36)が容器に設けてある。該開口は、空気流入口の役割を果たす。さらなる空気流入口(37)が後面(38)に設けてあり、これはインサート(31)の後端を閉鎖する。図3Cは、この後面の平面図を示す。開口の数と配置は変えることができる。 Figures 3A and 3B show a further embodiment (in perspective) of a device according to the invention, in which a tube or mouthpiece (30) into which a cylindrical insert (31) can be inserted. Is described. The internal space of the insert (31) is divided into two chambers (33, 34) by a dividing wall (32) extending in the longitudinal direction, which chambers serve to receive the active agent preparation and the acid component, respectively. Fulfills (not shown). The insert is surrounded by a cylindrical container (35) (in FIG. 3A this is shown partially cut away). In the rear end region, an opening (36) is provided in the container. The opening serves as an air inlet. A further air inlet (37) is provided in the rear face (38), which closes the rear end of the insert (31). FIG. 3C shows a plan view of this rear surface. The number and arrangement of openings can be varied.
ニコチン含有調製物は、製造の最中に、チャンバー(33、34)中に設置される。例えば、ニコチンを含浸させた担体材料(例えば、スポンジもしくは濾紙)と、揮発酸(好ましくは酢酸)を含浸させた担体材料とが、それぞれ別のチャンバー内に設置される。任意に、香味剤もしくは芳香剤を共に組み込んでもよい。全ての開口部、すなわち前端(V)、および開口(36、37)は、好適な保護フィルムもしくはホイルで閉鎖される。 The nicotine-containing preparation is placed in the chamber (33, 34) during manufacture. For example, a carrier material (eg, sponge or filter paper) impregnated with nicotine and a carrier material impregnated with a volatile acid (preferably acetic acid) are placed in separate chambers. Optionally, a flavoring or fragrance may be incorporated together. All openings, ie the front end (V), and the openings (36, 37) are closed with a suitable protective film or foil.
使用の前に、保護フィルムを除去し、インサート(31)をマウスピース(30)中に挿入する。マウスピースを吸うことにより、空気が2つの後部開口(36、37)を介して吸い込まれる。この空気は、2つのチャンバー(33、34)を通って、担体材料上を流れ、そうすることにより、ニコチン蒸気、酸蒸気、および任意に芳香剤蒸気を運ぶ。これらの蒸気は、口腔に入る前に、マウスピースの領域で渦流する。ニコチン蒸気と酸蒸気との混合は、ニコチンの吸入を促進する。この目的のために、マウスピース(30)に複数の突起もしくは歯(39)が備えられているのが有利である。これらは、好ましくは、次から次へ、複数のオフセット列(offset rows)で配置される。マウスピース(30)は、両端が開いた実質的に円筒状のスリーブである。これは、好ましくはインサート(31)より短い。
突起もしくは歯(39)は、らせん状、S字状もしくは渦巻状のバッフルとして構成されてもよく、これにより、より良好な空気の渦流、そしてしたがって、より良好な気体の混合が達成される。
Prior to use, the protective film is removed and the insert (31) is inserted into the mouthpiece (30). By sucking the mouthpiece, air is sucked through the two rear openings (36, 37). This air flows through the two chambers (33, 34) over the carrier material, thereby carrying nicotine vapor, acid vapor, and optionally fragrance vapor. These vapors vortex in the mouthpiece area before entering the oral cavity. Mixing nicotine vapor and acid vapor facilitates inhalation of nicotine. For this purpose, the mouthpiece (30) is advantageously provided with a plurality of protrusions or teeth (39). These are preferably arranged in a plurality of offset rows from next to next. The mouthpiece (30) is a substantially cylindrical sleeve open at both ends. This is preferably shorter than the insert (31).
The protrusions or teeth (39) may be configured as a helical, S-shaped or spiral baffle, which achieves better air vortex flow and therefore better gas mixing.
図4Aは、本発明によるデバイスのさらなる態様の透視断面像を示す。このデバイスは、スリーブ形状のマウスピース(30)を含み、該マウスピースには、チューブ(41)を回転可能に付着させることができるか、または、チューブを回転可能に滑り込ませることができるか、または、チューブ(41)を回転可能に挿入する(矢印の方向)ことができる。好ましくは、マウスピースの端部(40)は、チューブ(41)が、マウスピース上に滑り込ませたときにスナップ取り付けされるように構成される。マウスピースの口に面した開口には、図3に記載のとおり、複数の突起(39)が設けられている。マウスピース(40)の内部空間は、2つの分割壁により4つのチャンバーに分割されている。チューブ(41)と接続される開口部は、部分的に閉鎖している。好ましくは、マウスピースの実質的に円形の断面の少なくとも1つの扇状部、例えば、2つの対向する扇状部は、図4Bに示すとおり閉鎖されている。 FIG. 4A shows a perspective cross-sectional image of a further embodiment of the device according to the invention. The device includes a sleeve-shaped mouthpiece (30) to which the tube (41) can be rotatably attached or the tube can be rotatably slid, Alternatively, the tube (41) can be inserted rotatably (in the direction of the arrow). Preferably, the mouthpiece end (40) is configured to snap onto when the tube (41) is slid over the mouthpiece. The opening facing the mouth of the mouthpiece is provided with a plurality of protrusions (39) as shown in FIG. The internal space of the mouthpiece (40) is divided into four chambers by two dividing walls. The opening connected to the tube (41) is partially closed. Preferably, at least one sector of the substantially circular cross section of the mouthpiece, eg, two opposing sectors, is closed as shown in FIG. 4B.
スリップオンチューブ(41)は、両端が開いており、かつ、マウスピースと同様の様式で(壁(44、45)により)、内部が4つのチャンバーに分割されている。ニコチン含有調製物および酸含有調製物は、それぞれ、2つの対向するチャンバー内に位置する。マウスピースおよびチューブが2つもしくは3つ、または4つ以上の内部空間に分割されている態様もまた提供される。
壁もしくはバッフル(44、45)もまた、らせん状、S字状、または渦巻状に構成されていてもよく、これにより、より強い空気の渦流、そしてしたがって、より良好な気体の混合がなされる。
The slip-on tube (41) is open at both ends and is divided into four chambers in the same manner as the mouthpiece (by the walls (44, 45)). The nicotine-containing preparation and the acid-containing preparation are each located in two opposing chambers. Also provided are embodiments in which the mouthpiece and tube are divided into two or three, or four or more interior spaces.
The walls or baffles (44, 45) may also be configured in a spiral, S-shape, or spiral, which provides a stronger air vortex and, therefore, better gas mixing. .
ニコチン含有チューブは、ニコチン含有担体材料をチューブの第1のチャンバー内に挿入し、そして酸含有担体材料を、対応する向かい側のチャンバー内に挿入することにより製造される(任意に、芳香剤で修飾される)。その後、全ての開口部を好適なフィルムまたはホイルで閉鎖する。さらに、チューブの残りのチャンバーを、さらなる活性剤または芳香剤により充填することも可能である。 A nicotine-containing tube is manufactured by inserting a nicotine-containing carrier material into the first chamber of the tube and inserting the acid-containing carrier material into the corresponding opposite chamber (optionally modified with a fragrance. ) Thereafter, all openings are closed with a suitable film or foil. In addition, the remaining chamber of the tube can be filled with additional active agents or fragrances.
使用するには、保護フィルムを除去し、チューブ(41)をマウスピース(40)に滑り込ませ、スナップ取り付けする。チューブは、チューブをマウスピースに対して回転させることにより(二重矢印参照)充填されたチャンバーを開閉できるように、回転可能にはめ込まれる。これは、消費者に、吸入したい気流を調節する可能性をもたらす。必要に応じて、マウスピースおよびチューブのそれぞれの開放端は、脱着可能なキャップで閉鎖することができる。 To use, the protective film is removed and the tube (41) is slid into the mouthpiece (40) and snapped on. The tube is rotatably fitted so that the filled chamber can be opened and closed by rotating the tube relative to the mouthpiece (see double arrow). This gives the consumer the possibility to adjust the airflow they wish to inhale. If desired, the open end of each mouthpiece and tube can be closed with a removable cap.
図5は、図4に記載した態様の変更を示す(断面図で)。マウスピース(40)およびチューブ(41)の内部空間は、4つの管状のチャンバー(51、52、53、54)に分割されている。(50)は、マウスピースおよびチューブの円筒壁をそれぞれ示す。
この文脈において、活性剤または酸が含浸された担体材料を、「カートリッジ」の形態でチューブ内に挿入し得ることは有利である。この場合、チューブはマウスピースとユニットを形成し、これに恒久的に(しかし回転可能に)接続していることができる。これは、デバイス全体が再使用可能であることを意味する。「カートリッジ」は別々に保管しておくことができ、異なるニコチン含量を有するように(または異なる活性剤を含有するように)製造することができる。
FIG. 5 shows a modification of the embodiment described in FIG. 4 (in cross section). The interior space of the mouthpiece (40) and the tube (41) is divided into four tubular chambers (51, 52, 53, 54). (50) shows the mouthpiece and the cylindrical wall of the tube, respectively.
In this context, it is advantageous that a carrier material impregnated with an active agent or acid can be inserted into the tube in the form of a “cartridge”. In this case, the tube forms a unit with the mouthpiece and can be permanently (but rotatably) connected to it. This means that the entire device is reusable. “Cartridges” can be stored separately and can be manufactured to have different nicotine contents (or to contain different active agents).
図6は、本発明によるデバイスのさらなる有利な態様を図式的に示す。活性剤含有調製物(図示せず)は第1の区画(61)に位置し、これは、活性剤蒸気が集積することができるより大きな気体空間を形成する。酸含有調製物は、場合によっては芳香剤と組み合わされて、第2の区画(62)に位置する。太い矢印は、吸入中に生じる気流の方向を示す。空気は、流入口(64、65)を介して吸い込まれる。これらは、成分(活性剤、酸)の時期尚早な混合を防ぎ、および/または成分が外部に漏れることを防ぐために、弁を備えていてもよい。 FIG. 6 schematically shows a further advantageous embodiment of the device according to the invention. An activator-containing preparation (not shown) is located in the first compartment (61), which forms a larger gas space in which activator vapor can accumulate. The acid-containing preparation is located in the second compartment (62), optionally in combination with a fragrance. Thick arrows indicate the direction of airflow that occurs during inhalation. Air is sucked in through the inlets (64, 65). They may be equipped with valves to prevent premature mixing of the components (active agent, acid) and / or to prevent the components from leaking out.
マウスピース(63)を通して吸入すると、空気はデバイス内を2つの異なる経路に沿って流れる。(i)空気は、側部の開口(64)を通って区画(61)に流れ、その過程で、蒸気圧によって事前に飽和された気体空間を、マウスピース(63)の前部にある混合領域内に流し込む。(ii)同時に、空気は、側部の開口(65)を通って、第2の区画(62)に吸い込まれる。この過程で、この空気はまた、補助物質(酸、場合によっては芳香剤)を、マウスピース(63)の前部にある混合領域内に流し込む。混合領域において、2つの気流は互いに混じり合う。この混合過程の最中に、活性剤塩基の所望の中和が生じる。 When inhaled through the mouthpiece (63), air flows through the device along two different paths. (I) Air flows into the compartment (61) through the side opening (64), in the process, the gas space presaturated by the vapor pressure is mixed in the front part of the mouthpiece (63) Pour into the area. (Ii) At the same time, air is drawn into the second compartment (62) through the side opening (65). In this process, this air also flows auxiliary substances (acids, and possibly fragrances) into the mixing zone at the front of the mouthpiece (63). In the mixing zone, the two air streams mix with each other. During this mixing process, the desired neutralization of the activator base occurs.
Claims (23)
−ニコチン塩基または/および他の塩基性活性剤を含有する第1の調製物を含み、
−第2のもしくは複数の調製物であって、少なくとも1つの調製物が吸入に好適な少なくとも1つの揮発酸を含有する調製物を含み、
該デバイスが、第1の空気流入口、第2の空気流入口および空気流出口を有し、これにより第1の空気流入口を通って流れる気流が主として第1の調製物上を流れ、かつ、第2の空気流入口を通って流れる気流が主として第2のまたはさらなる調製物上を流れ、2つの気流がその後経路内で合わさり、前記流出口を通ってデバイスから出て行くようになっていることを特徴とする、前記デバイス。A device for administering a basic active agent, in particular nicotine, to the human or animal body by inhalation, the device comprising:
-A first preparation containing nicotine base or / and other basic active agent,
A second or plurality of preparations, at least one preparation comprising at least one volatile acid suitable for inhalation,
The device has a first air inlet, a second air inlet and an air outlet, whereby the airflow flowing through the first air inlet flows primarily over the first preparation; and The airflow flowing through the second air inlet primarily flows over the second or further preparation, and the two airflows then merge in the path and exit the device through the outlet. Said device, characterized in that
−第1の調製物を受けるための、縦長の窪んだ第1の凹部と、第2の調製物を受けるための、縦長の窪んだ第2の凹部とを含む成形部分を、好ましくは深絞りにより作製する工程、
−ニコチン塩基または他の塩基性活性剤を含有する所定量の第1の調製物を、前記第1の凹部に導入する工程、
−1種または2種以上の酸を含有する所定量の第2の調製物を、前記第2の凹部に導入する工程、
を含む、前記方法。A method for manufacturing a device according to any of claims 1 to 17, wherein the method comprises the following steps:
A molded part, preferably a deep draw, comprising a longitudinally depressed first recess for receiving the first preparation and a longitudinally recessed second recess for receiving the second preparation; The process of producing by
Introducing a predetermined amount of a first preparation containing a nicotine base or other basic active agent into the first recess,
Introducing a predetermined amount of a second preparation containing one or more acids into the second recess,
Said method.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10356925A DE10356925B4 (en) | 2003-12-05 | 2003-12-05 | Inhaler for basic active pharmaceutical ingredients and process for its preparation |
PCT/EP2004/012947 WO2005053444A1 (en) | 2003-12-05 | 2004-11-16 | Inhaler for basic pharmaceutical agents and method for production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007512880A JP2007512880A (en) | 2007-05-24 |
JP4516970B2 true JP4516970B2 (en) | 2010-08-04 |
Family
ID=34638403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006541822A Expired - Fee Related JP4516970B2 (en) | 2003-12-05 | 2004-11-16 | Inhaler for basic drugs and method for producing the same |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070062548A1 (en) |
EP (1) | EP1699309A1 (en) |
JP (1) | JP4516970B2 (en) |
CN (1) | CN1889861B (en) |
CA (1) | CA2546693A1 (en) |
DE (1) | DE10356925B4 (en) |
WO (1) | WO2005053444A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014115324A1 (en) * | 2013-01-28 | 2014-07-31 | 日本たばこ産業株式会社 | Non-heating flavor suction device |
JP2019504671A (en) * | 2016-01-11 | 2019-02-21 | サイケ メディカル リミテッドSyqe Medical Ltd. | Personal vaporizer |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8322350B2 (en) | 2004-12-30 | 2012-12-04 | Philip Morris Usa Inc. | Aerosol generator |
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
US9675109B2 (en) | 2005-07-19 | 2017-06-13 | J. T. International Sa | Method and system for vaporization of a substance |
DE202006001663U1 (en) * | 2006-02-03 | 2006-04-27 | Kieslich, Dirk | Smoke-free cigarette with nicotine and flavor cushions but without harmful combustion substances and side effects |
WO2008062453A2 (en) * | 2006-09-25 | 2008-05-29 | Nikki Nikhilesh Singh | Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form |
GB2461008B (en) * | 2006-12-08 | 2011-08-10 | Exchange Supplies Ltd | Nicotine inhalation device |
CN103418062B (en) * | 2007-03-30 | 2017-04-12 | 菲利普莫里斯生产公司 | Device and method for delivery of a medicament |
EP2218760B1 (en) * | 2007-11-30 | 2015-09-02 | Japan Tobacco Inc. | Aerosol-generating solution for aerosol aspirator |
EP2534957B1 (en) | 2007-12-14 | 2015-05-27 | AeroDesigns, Inc | Delivering aerosolizable products |
US8991402B2 (en) | 2007-12-18 | 2015-03-31 | Pax Labs, Inc. | Aerosol devices and methods for inhaling a substance and uses thereof |
AT507187B1 (en) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | INHALER |
UA105038C2 (en) * | 2009-03-17 | 2014-04-10 | Філіп Морріс Продактс С.А. | Tobacco-based nicotine aerosol generation system |
US8495998B2 (en) | 2009-06-17 | 2013-07-30 | British American Tobacco (Investments) Limited | Inhaler |
SE534196C2 (en) * | 2009-06-29 | 2011-05-31 | John Wollin | Nicotine dosing system |
CN102612361B (en) | 2009-09-16 | 2014-11-05 | 菲利普莫里斯生产公司 | Improved device and method for delivery of a medicament |
GB0918129D0 (en) | 2009-10-16 | 2009-12-02 | British American Tobacco Co | Control of puff profile |
DE102010000043A1 (en) | 2010-01-11 | 2011-07-14 | Lars 12587 Dähne | Inhaler system for volatile substances |
AT508244B1 (en) | 2010-03-10 | 2010-12-15 | Helmut Dr Buchberger | INHALATORKOMPONENTE |
US8952038B2 (en) | 2010-03-26 | 2015-02-10 | Philip Morris Usa Inc. | Inhibition of undesired sensory effects by the compound camphor |
EP2552245B1 (en) | 2010-03-26 | 2018-11-14 | Philip Morris Products S.A. | Inhibition of sensory irritation during consumption of non-smokeable tobacco products |
EP4397344A3 (en) | 2010-08-24 | 2024-10-02 | JT International SA | Inhalation device including substance usage controls |
CA2824970C (en) | 2011-02-11 | 2016-05-03 | Batmark Limited | Inhaler component |
AT510837B1 (en) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | INHALATORKOMPONENTE |
RU2595971C2 (en) | 2011-09-06 | 2016-08-27 | Бритиш Америкэн Тобэкко (Инвестментс) Лимитед | Heating smoking material |
EP3892125A3 (en) | 2011-09-06 | 2022-01-05 | Nicoventures Trading Limited | Heating smokable material |
DE102011083183A1 (en) * | 2011-09-22 | 2013-03-28 | Elke Martschina | Smokeless cigarette has depot element which is inserted between two ends of contour sleeve made of heat conducting metal material, and cigarette tube is pushed into contour sleeve |
AT511344B1 (en) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | INHALATORKOMPONENTE |
TW201340894A (en) * | 2011-12-20 | 2013-10-16 | British American Tobacco Co | Smoking articles and other flow delivery articles |
US9532597B2 (en) | 2012-02-22 | 2017-01-03 | Altria Client Services Llc | Electronic smoking article |
CN104254258B (en) * | 2012-04-12 | 2018-11-30 | Jt国际公司 | aerosol generating device |
GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
US10021907B2 (en) * | 2014-11-20 | 2018-07-17 | Kaloud, Inc. | Hookah bowl |
US20160143352A1 (en) * | 2012-06-06 | 2016-05-26 | Kaloud, Inc. | Head bowl accessory for a water pipe |
US10004259B2 (en) * | 2012-06-28 | 2018-06-26 | Rai Strategic Holdings, Inc. | Reservoir and heater system for controllable delivery of multiple aerosolizable materials in an electronic smoking article |
GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
US10517530B2 (en) | 2012-08-28 | 2019-12-31 | Juul Labs, Inc. | Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances |
US10031183B2 (en) | 2013-03-07 | 2018-07-24 | Rai Strategic Holdings, Inc. | Spent cartridge detection method and system for an electronic smoking article |
US20140261488A1 (en) * | 2013-03-15 | 2014-09-18 | Altria Client Services Inc. | Electronic smoking article |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
CA3208137A1 (en) | 2013-05-06 | 2014-11-13 | Juul Labs, Inc. | Nicotine salt formulations for aerosol devices and methods thereof |
US11202470B2 (en) | 2013-05-22 | 2021-12-21 | Njoy, Inc. | Compositions, devices, and methods for nicotine aerosol delivery |
GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
CN105473012B (en) | 2013-06-14 | 2020-06-19 | 尤尔实验室有限公司 | Multiple heating elements with individual vaporizable materials in electronic vaporization devices |
US9848645B2 (en) | 2013-07-24 | 2017-12-26 | Sis Resources Ltd. | Cartomizer structure for automated assembly |
RU2533949C1 (en) * | 2013-09-09 | 2014-11-27 | Дмитрий Анатольевич Семаков | Volatile drug inhaler |
RU2672649C2 (en) * | 2013-09-19 | 2018-11-16 | Филип Моррис Продактс С.А. | Aerosol-generating system for generating nicotine salt particles |
KR102665932B1 (en) | 2013-12-05 | 2024-05-13 | 쥴 랩스, 인크. | Nicotine liquid formulations for aerosol devices and methods thereof |
CN110664012A (en) | 2013-12-23 | 2020-01-10 | 尤尔实验室有限公司 | Evaporation apparatus system and method |
US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US9549573B2 (en) | 2013-12-23 | 2017-01-24 | Pax Labs, Inc. | Vaporization device systems and methods |
ES2526106B1 (en) | 2014-02-21 | 2016-05-06 | Armando MEDINA RIVERO | DEVICE FOR TESTING ELECTRONIC CIGARETTE LIQUIDS |
JP6712231B2 (en) | 2014-04-28 | 2020-06-17 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | Nicotine powder inhaler |
GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
KR102428028B1 (en) * | 2014-04-28 | 2022-08-03 | 필립모리스 프로덕츠 에스.에이. | Flavoured nicotine powder inhaler |
US11478021B2 (en) | 2014-05-16 | 2022-10-25 | Juul Labs, Inc. | Systems and methods for aerosolizing a vaporizable material |
TWI669073B (en) * | 2014-06-24 | 2019-08-21 | 瑞士商菲利浦莫里斯製品股份有限公司 | Aerosol-generating system, aerosol-generating article, aerosol-generating device and method of controlling the reaction stoichiometry |
GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
GB2529201A (en) | 2014-08-13 | 2016-02-17 | Batmark Ltd | Device and method |
US11350669B2 (en) | 2014-08-22 | 2022-06-07 | Njoy, Llc | Heating control for vaporizing device |
KR102574658B1 (en) | 2014-12-05 | 2023-09-05 | 쥴 랩스, 인크. | Calibrated dose control |
GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
GB201501951D0 (en) | 2015-02-05 | 2015-03-25 | Jt Int Sa | Aerosol guiding device and aerosol generating system comprising said aerosol guiding device |
CA2978384A1 (en) * | 2015-03-27 | 2016-10-06 | Philip Morris Products S.A. | Resealable aerosol-generating article |
GB201505597D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Article for use with apparatus for heating smokable material |
CA2984454C (en) * | 2015-05-01 | 2021-05-25 | Japan Tobacco Inc. | Non-burning type flavor inhaler, flavor source unit, and atomizing unit |
GB201511361D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic vapour provision system |
GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
US10251425B2 (en) | 2015-07-06 | 2019-04-09 | Njoy, Llc | Vaporizing device with power component |
USD809190S1 (en) | 2015-07-13 | 2018-01-30 | Njoy, Llc | Vaporizer |
US10039323B2 (en) | 2015-07-16 | 2018-08-07 | Njoy, Llc | Vaporizer tank with atomizer |
WO2017011865A1 (en) | 2015-07-20 | 2017-01-26 | Medical Developments International Limited | Inhaler device for inhalable liquids |
CN108348703A (en) * | 2015-07-20 | 2018-07-31 | 医疗发展国际有限公司 | Inhaler device for may be inhaled liquid |
EP3325063B1 (en) * | 2015-07-20 | 2022-10-05 | Medical Developments International Limited | Inhaler device for inhalable liquids |
US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
US12042809B2 (en) | 2015-11-02 | 2024-07-23 | Altria Client Services Llc | Aerosol-generating system comprising a vibratable element |
EP3370551B1 (en) * | 2015-11-02 | 2020-12-30 | Philip Morris Products S.a.s. | An aerosol-generating system comprising a vibratable element |
JP6818765B2 (en) * | 2015-12-21 | 2021-01-20 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | Aerosol generation system with variable air inlet |
PT3183980T (en) * | 2015-12-22 | 2018-11-23 | Philip Morris Products Sa | A cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge |
MX2018007311A (en) | 2015-12-22 | 2018-09-11 | Philip Morris Products Sa | A cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge. |
PT3183979T (en) * | 2015-12-22 | 2018-10-15 | Philip Morris Products Sa | Cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge |
WO2017108991A1 (en) * | 2015-12-22 | 2017-06-29 | Philip Morris Products S.A. | A cartridge for an aerosol-generating system and an aerosol-generating system comprising a cartridge |
SG10202108578XA (en) | 2016-02-11 | 2021-09-29 | Juul Labs Inc | Securely attaching cartridges for vaporizer devices |
UA125687C2 (en) | 2016-02-11 | 2022-05-18 | Джуул Лебз, Інк. | Fillable vaporizer cartridge and method of filling |
GB201602831D0 (en) * | 2016-02-18 | 2016-04-06 | British American Tobacco Co | Flavour delivery device |
US10455863B2 (en) | 2016-03-03 | 2019-10-29 | Altria Client Services Llc | Cartridge for electronic vaping device |
US10433580B2 (en) | 2016-03-03 | 2019-10-08 | Altria Client Services Llc | Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge |
US10368580B2 (en) | 2016-03-08 | 2019-08-06 | Altria Client Services Llc | Combined cartridge for electronic vaping device |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
US10357060B2 (en) | 2016-03-11 | 2019-07-23 | Altria Client Services Llc | E-vaping device cartridge holder |
US10368581B2 (en) | 2016-03-11 | 2019-08-06 | Altria Client Services Llc | Multiple dispersion generator e-vaping device |
KR20210009450A (en) | 2016-04-27 | 2021-01-26 | 니코벤처스 트레이딩 리미티드 | Electronic aerosol provision system and vaporizer therefor |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
CN106063583A (en) * | 2016-07-14 | 2016-11-02 | 深圳昱朋科技有限公司 | The preparation method of ree-oil additive and ree-oil |
US11660403B2 (en) | 2016-09-22 | 2023-05-30 | Juul Labs, Inc. | Leak-resistant vaporizer device |
KR102327122B1 (en) | 2016-12-12 | 2021-11-16 | 브이엠알 프로덕츠 엘엘씨 | carburetor cartridge |
GB201702206D0 (en) | 2017-02-10 | 2017-03-29 | British American Tobacco Investments Ltd | Vapour provision system |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
GB201721477D0 (en) | 2017-12-20 | 2018-01-31 | British American Tobacco Investments Ltd | Electronic aerosol provision system |
GB201721470D0 (en) | 2017-12-20 | 2018-01-31 | British American Tobacco Investments Ltd | Electronic aerosol provision system |
GB201721447D0 (en) | 2017-12-20 | 2018-01-31 | British American Tobacco Investments Ltd | Electronic aerosol provision system |
KR102701417B1 (en) * | 2018-06-21 | 2024-09-03 | 필립모리스 프로덕츠 에스.에이. | Activable reclosable cartridge assembly for aerosol generating systems |
KR20210135581A (en) * | 2019-03-11 | 2021-11-15 | 니코벤처스 트레이딩 리미티드 | aerosol generation |
US11998050B2 (en) * | 2020-06-23 | 2024-06-04 | Altria Client Services Llc | Capsules with internal channels, heat-not-burn (HNB) aerosol-generating devices, and methods of generating an aerosol |
KR102527343B1 (en) * | 2020-10-23 | 2023-05-02 | 주식회사 케이티앤지 | Aerosol generating article comprising liquid composition and aerosol generating system comprising the same |
MX2024007561A (en) * | 2021-12-20 | 2024-07-04 | Nicoventures Trading Ltd | A consumable for use with an aerosol provision device. |
WO2024133707A1 (en) * | 2022-12-23 | 2024-06-27 | Philip Morris Products S.A. | Aerosol-generating article comprising a frame |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US726037A (en) * | 1901-06-22 | 1903-04-21 | Henry Ferre | Tubular inhaler. |
GB1017032A (en) * | 1963-12-12 | 1966-01-12 | Aerosmoke Ltd | Aerosol compositions |
US4284089A (en) * | 1978-10-02 | 1981-08-18 | Ray Jon P | Simulated smoking device |
US4800903A (en) * | 1985-05-24 | 1989-01-31 | Ray Jon P | Nicotine dispenser with polymeric reservoir of nicotine |
AT384552B (en) * | 1985-08-01 | 1987-12-10 | Hurka Wilhelm | INHALATION DEVICE FOR DOSING AND DISTRIBUTING SOLID BODIES INTO THE BREATHING AIR |
US4793366A (en) * | 1985-11-12 | 1988-12-27 | Hill Ira D | Nicotine dispensing device and methods of making the same |
US4917120A (en) * | 1986-05-21 | 1990-04-17 | Advanced Tobacco Products, Inc. | Nicotine impact modification |
US4765348A (en) * | 1986-12-12 | 1988-08-23 | Brown & Williamson Tobacco Corporation | Non-combustible simulated cigarette device |
US5167242A (en) * | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
SE9002895D0 (en) * | 1990-09-12 | 1990-09-12 | Astra Ab | INHALATION DEVICES FOR DISPENSING POWDERS I |
US5441060A (en) * | 1993-02-08 | 1995-08-15 | Duke University | Dry powder delivery system |
US5362496A (en) * | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
DE19546024C2 (en) * | 1995-12-09 | 1998-09-10 | Lohmann Therapie Syst Lts | Transdermal pharmaceutical preparation and its production |
US20030051728A1 (en) * | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
WO2003045484A2 (en) * | 2001-11-21 | 2003-06-05 | Alexza Molecular Delivery Corporation | Open-celled substrates for drug delivery |
GB2388040B (en) * | 2002-05-02 | 2005-12-14 | Robert Jeremy West | Nicotine inhalation device |
DE602004019430D1 (en) * | 2003-09-08 | 2009-03-26 | Mcneil Ab | NICOTINE FORMULATIONS AND THEIR USE |
-
2003
- 2003-12-05 DE DE10356925A patent/DE10356925B4/en not_active Expired - Fee Related
-
2004
- 2004-11-16 JP JP2006541822A patent/JP4516970B2/en not_active Expired - Fee Related
- 2004-11-16 WO PCT/EP2004/012947 patent/WO2005053444A1/en active Application Filing
- 2004-11-16 EP EP04797909A patent/EP1699309A1/en not_active Withdrawn
- 2004-11-16 CN CN2004800361875A patent/CN1889861B/en not_active Expired - Fee Related
- 2004-11-16 US US10/581,867 patent/US20070062548A1/en not_active Abandoned
- 2004-11-16 CA CA002546693A patent/CA2546693A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014115324A1 (en) * | 2013-01-28 | 2014-07-31 | 日本たばこ産業株式会社 | Non-heating flavor suction device |
JP2019504671A (en) * | 2016-01-11 | 2019-02-21 | サイケ メディカル リミテッドSyqe Medical Ltd. | Personal vaporizer |
US11229758B2 (en) | 2016-01-11 | 2022-01-25 | Syqe Medical Ltd. | Personal vaporizing device with slidable cart |
Also Published As
Publication number | Publication date |
---|---|
US20070062548A1 (en) | 2007-03-22 |
EP1699309A1 (en) | 2006-09-13 |
CN1889861A (en) | 2007-01-03 |
CA2546693A1 (en) | 2005-06-16 |
JP2007512880A (en) | 2007-05-24 |
WO2005053444A1 (en) | 2005-06-16 |
CN1889861B (en) | 2010-11-17 |
DE10356925A1 (en) | 2005-07-14 |
DE10356925B4 (en) | 2006-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4516970B2 (en) | Inhaler for basic drugs and method for producing the same | |
AU2014365123B2 (en) | Aerosol-generating system for generating and controlling the quantity of nicotine salt particles | |
CA2377625C (en) | Systems and methods for aerosolizing pharmaceutical formulations | |
US11020550B2 (en) | Device and system | |
CN111818955B (en) | Inhaler with composite porous support element | |
JPH0271760A (en) | Inhalation metering type drug aerosol distribution and administration apparatus | |
AU2016247916B2 (en) | Flavoring element for an inhalation device | |
JPH0623048A (en) | Apparatus for oral inhalation of aerosol drug | |
CN109219462B (en) | Nicotine particle delivery consumable | |
EP3941231B1 (en) | Fluid transfer article | |
GB2310607A (en) | Spacer device for inhalers | |
US6981660B2 (en) | Shock wave aerosolization apparatus and method | |
EP3941556B1 (en) | Aerosol delivery system | |
RU2783305C2 (en) | Inhaler with composite porous support element | |
KR20230026666A (en) | Nicotine inhaler | |
MXPA06006284A (en) | Portable gas operating inhaler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100405 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100511 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100517 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130521 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |